279 related articles for article (PubMed ID: 27783278)
1. Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Kotsopoulos J; Singer C; Narod SA
Breast Cancer Res Treat; 2017 Jan; 161(1):11-16. PubMed ID: 27783278
[TBL] [Abstract][Full Text] [Related]
2. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
[TBL] [Abstract][Full Text] [Related]
3. Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.
Widschwendter M; Burnell M; Fraser L; Rosenthal AN; Philpott S; Reisel D; Dubeau L; Cline M; Pan Y; Yi PC; Gareth Evans D; Jacobs IJ; Menon U; Wood CE; Dougall WC
EBioMedicine; 2015 Oct; 2(10):1331-9. PubMed ID: 26629528
[TBL] [Abstract][Full Text] [Related]
4. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
5. RANKL/RANK: from bone loss to the prevention of breast cancer.
Sigl V; Jones LP; Penninger JM
Open Biol; 2016 Nov; 6(11):. PubMed ID: 27881737
[TBL] [Abstract][Full Text] [Related]
6. Role of the RANK/RANKL pathway in breast cancer.
Kiesel L; Kohl A
Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
[TBL] [Abstract][Full Text] [Related]
7. RANKL and RANK: From Mammalian Physiology to Cancer Treatment.
Rao S; Cronin SJF; Sigl V; Penninger JM
Trends Cell Biol; 2018 Mar; 28(3):213-223. PubMed ID: 29241686
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
Cuyàs E; Corominas-Faja B; Martín MM; Martin-Castillo B; Lupu R; Brunet J; Bosch-Barrera J; Menendez JA
Oncotarget; 2017 May; 8(21):35019-35032. PubMed ID: 28388533
[TBL] [Abstract][Full Text] [Related]
9. Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Odén L; Akbari M; Zaman T; Singer CF; Sun P; Narod SA; Salmena L; Kotsopoulos J
Oncotarget; 2016 Dec; 7(52):86687-86694. PubMed ID: 27893411
[TBL] [Abstract][Full Text] [Related]
10. RANKL/RANK control Brca1 mutation- .
Sigl V; Owusu-Boaitey K; Joshi PA; Kavirayani A; Wirnsberger G; Novatchkova M; Kozieradzki I; Schramek D; Edokobi N; Hersl J; Sampson A; Odai-Afotey A; Lazaro C; Gonzalez-Suarez E; Pujana MA; Cimba F; Heyn H; Vidal E; Cruickshank J; Berman H; Sarao R; Ticevic M; Uribesalgo I; Tortola L; Rao S; Tan Y; Pfeiler G; Lee EY; Bago-Horvath Z; Kenner L; Popper H; Singer C; Khokha R; Jones LP; Penninger JM
Cell Res; 2016 Jul; 26(7):761-74. PubMed ID: 27241552
[TBL] [Abstract][Full Text] [Related]
11. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
12. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
13. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.
Kiechl S; Schramek D; Widschwendter M; Fourkala EO; Zaikin A; Jones A; Jaeger B; Rack B; Janni W; Scholz C; Willeit J; Weger S; Mayr A; Teschendorff A; Rosenthal A; Fraser L; Philpott S; Dubeau L; Keshtgar M; Roylance R; Jacobs IJ; Menon U; Schett G; Penninger JM
Oncotarget; 2017 Jan; 8(3):3811-3825. PubMed ID: 28002811
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
15. Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.
Cuyàs E; Martin-Castillo B; Bosch-Barrera J; Menendez JA
Cell Cycle; 2017 Jun; 16(11):1022-1028. PubMed ID: 28387573
[TBL] [Abstract][Full Text] [Related]
16. Out-RANKing BRCA1 in Mutation Carriers.
Nolan E; Lindeman GJ; Visvader JE
Cancer Res; 2017 Feb; 77(3):595-600. PubMed ID: 28104682
[TBL] [Abstract][Full Text] [Related]
17. NF-κB at the Crossroads of Normal Mammary Gland Biology and the Pathogenesis and Prevention of
Sau A; Cabrita MA; Pratt MAC
Cancer Prev Res (Phila); 2018 Feb; 11(2):69-80. PubMed ID: 29101208
[TBL] [Abstract][Full Text] [Related]
18. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
19. [Control of bone resorption by RANKL-RANK system].
Harada S; Takahashi N
Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
[TBL] [Abstract][Full Text] [Related]
20. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T; Feng X
Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
